William Miller, MD
Urology · Oklahoma City, OKNPI 1811988835
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,919 of the $6,966 with a category attached, or 85.0%. It is spread thinly across 46 manufacturers, the largest accounting for just 17.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $2,120 and has fallen 60.6% since, to $836 in 2025.
Across 298 payments — averaging $23.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Procept Biorobotics Corporation$1K
- Astellas Pharma US Inc$880
- Pfizer$627
- AbbVie$593
- Boston Scientific$434
- Urogen Pharma, Inc.$301
- plus $3K from 40 others
What the payments were for
- Travel & lodging$1,02315%
- Food & beverage$5,91985%
- Education$240%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AquaBeam Robotic System$1,150
- JELMYTO$159
- REZUM$111
How this compares
$6,966 in reported general payments places this provider in the 65th percentile of 145 urology providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 27 | $376,396 |
| MyrbetriqMirabegron | 168 | $106,081 |
| GemtesaVibegron | 50 | $32,661 |
| Methenamine Hippurate | 96 | $7,078 |
| Tamsulosin Hcl | 457 | $6,969 |
| Solifenacin Succinate | 106 | $6,897 |
| Finasteride | 437 | $5,721 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 229 | $3,778 |
| Fesoterodine Fumarate ErFesoterodine Fumarate | 24 | $3,417 |
| NitrofurantoinNitrofurantoin Macrocrystal | 118 | $3,393 |
| Silodosin | 49 | $2,553 |
| Tolterodine Tartrate ErTolterodine Tartrate | 34 | $2,043 |
| Potassium Citrate ErPotassium Citrate | 24 | $1,880 |
| Trospium Chloride | 38 | $1,664 |
| Oxybutynin Chloride ErOxybutynin Chloride | 44 | $1,255 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi, Myrbetriq | $880 | $482,477195 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $171 | $32,66150 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 145 urology providers in Oklahoma.
Other urology in Oklahoma City
- Mohammad RamadanOklahoma City$207K
- Michael CooksonOklahoma City$132K
- Kelly StrattonOklahoma City$62K
- Ashley BowenOklahoma City$32K
- Sardar Mohammad Khan GalzieOklahoma City$25K
- Basel HassounOklahoma City$20K
- Johnny HicksonOklahoma City$16K
- Michael HolzerOklahoma City$15K
- Dominic FrimbergerOklahoma City$12K
- Aaron BenhamOklahoma City$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.